Hemato Oncology Testing Market worth $5.6 billion by 2027 - Exclusive Report by MarketsandMarkets™

According to the new market research report "Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin's Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024", published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays.

Click the link to get a Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

[116 Pages Report] The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period.

This market study covers and analyzes the potential of the global Hemato-Oncology Testing Market industry, providing geometric information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy analysis, opportunities and forecasts. One of the major highpoints of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19 on Hemato-Oncology Testing Market.

Hemato-Oncology Testing Market: Competition Landscape

The Hemato-Oncology Testing Market report includes information on the product presentations, sustainability and prospects of leading player including: F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US)

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

Hemato-Oncology Testing Market: Segmentation

Hemato oncology testing Market, by Product & Service

• Services
• Assay Kits

Hemato oncology testing Market, by Cancer Type

• Leukemia
  • Acute myeloid leukemia
  • Acute lymphocytic leukemia
  • Other leukemia (Chronic lymphocytic leukemia, chronic myeloid leukemia)
• lymphoma
  • non-Hodgkin’s Lymphoma
  • Hodgkin’s Lymphoma
• Other cancers (Myeloma, Myelofibrosis (MF), Essential Thrombocythemia)

Hemato oncology testing Market, by Technology

• PCR
• IHC
• NGS
• Cytogenetics
• Others

Hemato oncology testing Market, by End User 

• Clinical laboratories
• Hospitals
• Academic & Research Institutes
• Other End Users (CROs, Pharmaceutical & Biotechnology Companies)

Hemato-Oncology Testing Market: Regional Analysis

All the regional segmentation has been studied based on recent and future trends and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Hemato-Oncology Testing Market report are North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and Latin America.

Key Benefits of the report:

• This study presents the analytical description of the global Hemato-Oncology Testing Market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Hemato-Oncology Testing Market share.
• The current market is quantitatively analyzed from 2022 to 2026 to highlight the global Hemato-Oncology Testing Market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & sellers in the market.
• The report provides a detailed global Hemato-Oncology Testing Market analysis based on competitive intensity and how the competition will take shape in the coming years.

Make an Enquire to Buy This Report @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=262472877

North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021

The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.

The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Related Reports:

Molecular Diagnostics Market - Global Forecasts to 2027

Infectious Disease Diagnostics Market - Global Forecasts to 2027 

Article source: https://article-realm.com/article/Health-Fitness/Fitness-Equipment/36307-Hemato-Oncology-Testing-Market-worth-5-6-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html